SHC stock forecast, quote, news & analysis
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers... Show more
Sotera Health (SHC) Stock Analysis: Durable MedTech Demand Meets a Regulatory Overhang
Key Takeaways
- Sotera Health shares were trading near $16.90 in early November 2026, down roughly 7% over the trailing 30 days, keeping the stock in a relatively narrow range rather than a sharp directional move.
- Third-quarter 2026 revenue rose 4.4% year over year to $324.9 million, topping consensus estimates, while adjusted EPS of $0.29 came in ahead of the $0.27 analysts expected.
- Management reconfirmed full-year 2026 guidance, including reported revenue of approximately $1.24 billion and adjusted EPS of $0.98 at the midpoint.
- Wall Street remains broadly constructive, with Buy ratings from firms including RBC Capital, Barclays, and Goldman Sachs, though J.P. Morgan moved to the sidelines in October as part of a broader life sciences coverage review.
- Key watch items include Nordion shipment timing, MedTech procedure-volume trends, and the ongoing ethylene oxide (EO) regulatory process.
- For additional detail, explore Sotera Health's Price Targets, Earnings, and Forecast pages.
- Interested in automated trading insights? Explore Trending AI Robots.
Current Market Snapshot
Sotera Health Company (SHC) has traded in a comparatively tight band in recent weeks. After closing near $18.22 in early October 2026, the stock drifted to roughly $16.90 by early November, a decline of about 7% over the trailing 30 days. The move was modest relative to the stock's historical volatility, and much of October was spent oscillating between the high-$17 and mid-$18 range.
The broader healthcare services and life sciences tools segment has been mixed as investors weigh steady MedTech demand against regulatory uncertainty and softer procedure volumes reported by some providers. Against that backdrop, Sotera Health's valuation and recurring-revenue profile have kept it in focus for investors seeking exposure to the medical-device sterilization and testing supply chain.
Sotera Health (SHC) Business Overview and Competitive Position
Sotera Health is a leading global provider of mission-critical sterilization, lab testing, and advisory services for the healthcare industry. The company operates through three segments: Sterigenics, which provides outsourced terminal sterilization and irradiation using gamma, ethylene oxide (EO), and electron-beam technologies; Nordion, a supplier of Cobalt-60 and gamma irradiation systems; and Nelson Labs, which offers microbiological and analytical chemistry testing and advisory services for medical-device and pharmaceutical customers.
The company's value proposition rests on its role as a regulatory-required partner in the healthcare supply chain. Sterilization and testing are typically non-discretionary steps before medical devices and pharmaceuticals can reach patients, which supports a recurring, relatively resilient revenue stream. Sotera Health has also cited more than two decades of consecutive annual revenue growth, underpinned by long-term customer relationships and pricing power in a consolidated market with meaningful barriers to entry.
Recent Developments Driving SHC
Sotera Health's third-quarter 2026 results, reported in early November, showed revenue of $324.9 million, up 4.4% year over year and modestly ahead of consensus. Adjusted EPS of $0.29 exceeded the $0.27 estimate, while adjusted EBITDA of $170.7 million also topped expectations. Segment performance was mixed: Sterigenics and Nelson Labs delivered solid growth, while Nordion revenue declined 12.4% year over year on lower volume, partly offset by favorable pricing.
Earlier in the year, second-quarter results prompted management to raise its full-year 2026 outlook, and the company maintained that guidance through the third quarter, citing a stable demand environment in MedTech and pharma. The balance sheet also improved, with net leverage falling to 2.9 times and a credit-rating upgrade from Moody's in early October.
On the analyst front, RBC Capital, Barclays, and Goldman Sachs have each maintained Buy ratings in recent months, while J.P. Morgan downgraded the stock in October as part of a review of its life sciences coverage. The company continues to invest in capacity, including an X-ray sterilization facility in North Carolina, and has deployed roughly $200 million toward EO emission-control upgrades as the regulatory rulemaking process advances.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a broader platform offering hundreds of bots that trade thousands of tickers. Rather than listing every available strategy, the section highlights top-performing and most relevant robots so traders can quickly identify tools aligned with current market conditions. These bots vary by strategy, timeframe, and performance metrics, giving users a range of approaches to evaluate based on their own goals and risk tolerance. For those seeking to complement their own research with systematic, data-driven signals, the page offers a practical starting point for exploring automated trading ideas.
2026 Outlook and What Investors Should Watch
For the remainder of 2026, Sotera Health has guided to constant-currency revenue growth of 5.25% to 6.75%, with reported revenue of $1.233 billion to $1.250 billion and adjusted EBITDA of $632 million to $641 million. Management expects full-year adjusted EPS of $0.95 to $1.01, with the midpoint around $0.98.
Investors are likely to focus on several factors in the months ahead. Nordion's volume trajectory and shipment timing will remain a swing factor, while Sterigenics' growth will depend on underlying MedTech procedure volumes and customer demand. The eventual outcome of the EO regulatory process represents the most significant structural overhang, given the company's investments in emissions controls and the potential for further compliance requirements. Pricing trends, free-cash-flow generation, and any updates to the company's leverage-reduction progress will also shape sentiment as the year concludes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SHC's RSI Indicator ascending out of oversold territory
The RSI Oscillator for SHC moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 28 of the 37 cases the stock moved higher. This puts the odds of a move higher at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where SHC advanced for three days, in 186 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
SHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SHC as a result. In 60 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for SHC turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 27 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
SHC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for SHC entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. SHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.864) is normal, around the industry mean (67.298). P/E Ratio (28.088) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.313) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties